n.a. (ANX)

0.73
AMEX
Prev Close 0.73
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange AMEX
Div & Yield N.A. (N.A)

Latest News

ADVENTRX Stock Gaps Down On Today's Open (ANX)

Shares of ADVENTRX Pharmaceuticals (AMEX:ANX) were gapping down Friday morning with an open price 21.5% lower than Thursday's closing price. The stock closed at 93 cents yesterday and opened today's trading at 73 cents.

5 Stocks Under $10 Setting Up to Trade Higher

These under-$10 stocks look poised to break out and trade higher from current levels.

5 Stocks Setting Up to Break Out

5 Stocks Setting Up to Break Out

These stocks look poised to break out and trade higher from current levels.

ADVENTRX Stock Hits New 52-Week Low (ANX)

ADVENTRX Pharmaceuticals (AMEX:ANX) hit a new 52-week low Wednesday as it is currently trading at $1.04, below its previous 52-week low of $1.73 with 1.5 million shares traded as of 9:38 a.m. ET. Average volume has been 1.1 million shares over the past 30 days.

Adventrx: FDA Rejects Lung Cancer Drug

Adventrx's latest screw up raises serious questions about the company's ability to develop any drugs at all.

ADVENTRX Stock Gaps Down On Today's Open (ANX)

Shares of ADVENTRX Pharmaceuticals (AMEX:ANX) were gapping down Monday morning with an open price 11.4% lower than Friday's closing price. The stock closed at $2.46 yesterday and opened today's trading at $2.18.

Biotech Stock Mailbag: Sangamo Biosciences

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Biotech Stock Live Chat

TheStreet's biotech columnist Adam Feuerstein is holding a live, interactive discussion about biotech stock investing.

Biotech Stock Mailbag: Adventrx Pharma

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

More Hot Biotech Trades for Second Half 2011

These looming FDA drug approvals and clinical trial results are pivotal events in the lifeline of a biotech company.

Biotech Stock Mailbag: Generex Bio

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Biotech Calendar: 2011 FDA Drug Approvals

An updated list of drug and biotech firms with drug approvals expected in 2011.

Biotech Stock Mailbag: Cyclacel Pharma

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

India Globalization Capital, China BAK Battery: Midday Volume Plays

Several stocks trading near $5 were moving on above-average volume during Tuesday's session.

Biotech Stock Mailbag: Vertex Pharma

Senior columnist Adam Feuerstein answers readers' questions about Vertex Pharmaceuticals and other biotech and drug-related stocks.

Sirius XM, Wave Systems: Early Volume Plays

Several stocks trading near $5 were moving on above-average volume during Friday's session.

Biotech Stock Mailbag: Health Discovery

Our senior biotech columnist answers readers' questions about Health Discovery, Discovery Labs and other newsworthy healthcare stocks.

Biotech Stock Mailbag: GenVec

Senior columnist Adam Feuerstein responds to readers' biotech stock questions -- and lets Adventrx Pharmaceuticals' CEO sound off in response to a couple recent columns.

Digging Deeper Into Adventrx Pharmaceuticals

We take another look at the sales prospects for Adventrx's chemo drug ANX-530.

Biotech Stock Mailbag: Adventrx Pharmaceuticals

Fresh from the J.P. Morgan Healthcare Conference in San Francisco, columnist Adam Feuerstein answers readers' questions about hot-topic stocks.

J.P. Morgan Healthcare Confab: Preview

A rundown of what to expect at next week's San Francisco biotech conference.

Midday Movers: Pump Up the Volume

Several small-cap stocks were moving on above-average volume during Tuesday's session.

Icahn Angles for Biogen Board Seats

Activist investor Carl Icahn has nominated three people to the company's board.

Monday's Health Winners & Losers

Discovery Laboratories is rising.

Adventrx Sinks as Study Fails

The cancer drug ANX-510 disappoints, and shares drop 75%.

Thursday's Small-Cap Winners & Losers

Winthrop Realty Trust surges.

Tuesday's Health Winners & Losers

ImClone is falling.

Adventrx to Start Drug Trial

The study will involve CoFactor for treating advanced breast cancer.